Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore SARS-CoV-2 Sequencing Test Gets CE Mark

NEW YORK – Oxford Nanopore Technologies said on Friday that its LamPore SARS-CoV-2 sequencing test has obtained the CE mark for use with the GridIon platform.

The assay, which combines loop-mediated isotheral amplification (LAMP) with nanopore sequencing and can run on the GridIon and MinIon Mk1C platforms, targets the ORF1a, E, and N genes of the virus. Last month, researchers in the UK published a preprint of a validation study involving around 500 clinical samples, showing that the test is highly reproducible and has a sensitivity of 99.1 percent and a specificity of 99.6 percent.

Oxford Nanopore is rolling the LamPore test out globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates, according to a company statement.

It is also pursuing regulatory approvals in other countries, including Emergency Use Authorization in the US and, in collaboration with G42, authorization in the United Arab Emirates.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.